Back to top

pharmaceuticals: Archive

Derek Lewis

These 3 Companies are Seeing Supercharged Sales Growth

The 2025 Q2 earnings season is now behind us, with the period largely positive and resilient. Throughout the period, these three companies posted notably strong sales growth.

LLYPositive Net Change ETNNegative Net Change IBKRPositive Net Change

Sundeep Ganoria

Viking Therapeutics Loses 20% in a Month: How to Play the Stock

VKTX stock slumps after mixed obesity pill study results raise safety concerns and highlight fierce market competition.

NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change

Ahan Chakraborty

Is DefenCath Sufficient to Support CorMedix's Long-Term Growth Path?

CRMD's DefenCath, its only revenue source, posts $78.8M in sales in H1 2025, with exclusivity through 2033 fueling growth potential.

PFEPositive Net Change AMPHPositive Net Change CRMDNegative Net Change

Ekta Bagri

Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth?

Bristol Myers expects mid to high-single-digit sales growth for Opdivo and Qvantig in 2025 as approvals and launches gain momentum.

RHHBYPositive Net Change BMYPositive Net Change MRKPositive Net Change

Kinjel Shah

Eli Lilly's New Drugs Beyond Mounjaro and Zepbound Boost Sales

Eli Lilly's growing lineup beyond Mounjaro and Zepbound, including Omvoh and Jaypirca, is set to fuel revenue growth through 2025.

BIIBPositive Net Change JNJPositive Net Change LLYPositive Net Change ABBVPositive Net Change

Kinjel Shah

GSK Adds Around $5B in a Month: Here's How to Play the Stock

GSK stock adds nearly $5B in value in a month as Specialty Medicines growth, pipeline wins and a strong outlook outweigh vaccine headwinds.

GSKNegative Net Change NVONegative Net Change LLYPositive Net Change ABBVPositive Net Change

Abhinab Dasgupta

Beat the Market the Zacks Way: Oracle, Intellia, Pharming Group in Focus

Even in a choppy market, Zacks' strategies are spotlighting winners like Oracle, Intellia, and Pharming Group, proving the value of a disciplined, research-driven approach.

FASTNegative Net Change TMONegative Net Change TSCONegative Net Change ORCLNegative Net Change MTZNegative Net Change LPGNegative Net Change LITENegative Net Change NTLAPositive Net Change FSBWNegative Net Change CBRENegative Net Change PHARNegative Net Change

Zacks Equity Research

Sanofi Gets FDA Nod for Wayrilz in Immune Thrombocytopenia

SNY wins FDA approval for Wayrilz, the first BTK inhibitor for immune thrombocytopenia, with broader rare disease studies underway.

SNYNegative Net Change ADPTNegative Net Change AKRONegative Net Change ALGSPositive Net Change

Kinjel Shah

Pfizer's Golden Cross Signals Strength: How to Play the Stock

Pfizer trades above key SMAs with a golden cross, while new drugs and cost cuts drive growth despite looming headwinds.

PFEPositive Net Change NVONegative Net Change LLYPositive Net Change ABBVPositive Net Change

Ahan Chakraborty

NVO's Wegovy vs. LLY's Tirzepatide: Who Leads in Heart Risk Reduction?

Novo Nordisk's Wegovy shows a stronger reduction in heart risks compared to Eli Lilly's tirzepatide in real-world data from the STEER study.

NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change

Zacks Equity Research

ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win

Alnylam and Roche report positive phase II KARDIA-3 results for zilebesiran in high-risk hypertension patients, fueling momentum for a phase III study.

ALNYPositive Net Change RHHBYPositive Net Change CRMDNegative Net Change KNSAPositive Net Change

Zacks Equity Research

Biogen Secures FDA Nod for Subcutaneous Maintenance Dosing of Leqembi

BIIB wins FDA approval for Leqembi Iqlik, a fast, subcutaneous option for early Alzheimer's patients transitioning from IV infusions.

BIIBPositive Net Change LLYPositive Net Change ANIPPositive Net Change CRMDNegative Net Change

Zacks Equity Research

The Zacks Analyst Blog Highlights Lilly, Oracle, Procter & Gamble and Comstock Holding Companies

Zacks spotlights Eli Lilly, Oracle, Procter & Gamble, and microcap Comstock Holding, with pharma and staples facing pressure while Oracle and Comstock show momentum.

PGPositive Net Change LLYPositive Net Change ORCLNegative Net Change CHCINegative Net Change

Zacks Equity Research

Is ELV's Push Beyond Insurance a Blueprint for the Healthcare Future?

Elevance Health expands beyond insurance into primary care, digital health and pharmacy services, aiming to reshape healthcare delivery.

UNHPositive Net Change HUMPositive Net Change ELVPositive Net Change

Zacks Equity Research

Boyd Gaming and Shoe Carnival have been highlighted as Zacks Bull and Bear of the Day

Boyd Gaming surges on strong earnings and growth plans, while Shoe Carnival struggles with sliding sales and weaker momentum.

PFEPositive Net Change MRNANegative Net Change BYDNegative Net Change NVAXPositive Net Change SCVLPositive Net Change

Zacks Equity Research

J&J Ends Imaavy Development in Rheumatoid Arthritis Post Study Failure

JNJ halts Imaavy's rheumatoid arthritis program after trial results showed no added benefit over existing therapy.

JNJPositive Net Change ANIPPositive Net Change CRMDNegative Net Change

Zacks Equity Research

OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug

Outlook Therapeutics stock plunges 54% after the FDA rejects ONS-5010 BLA again, citing lack of efficacy data in confirmatory study.

CRMDNegative Net Change KNSAPositive Net Change OTLKPositive Net Change PHARNegative Net Change

Kinjel Shah

ABBV or MRK: Which Stock Should Investors Place Their Bet on in 2025?

AbbVie edges past Merck in 2025 as strong Skyrizi and Rinvoq sales, pipeline gains and rising estimates fuel growth momentum.

JNJPositive Net Change MRKPositive Net Change LLYPositive Net Change ABBVPositive Net Change

Mark Vickery

Top Stock Reports for Eli Lilly, Oracle & Procter & Gamble

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly, Oracle, and Procter & Gamble, as well as a micro-cap stock, Comstock.

PGPositive Net Change LLYPositive Net Change UNPNegative Net Change CVSPositive Net Change ORCLNegative Net Change BKRNegative Net Change CHCINegative Net Change

Zacks Equity Research

MRK, Daiichi Begin Phase III Breast Cancer Study With ADC Candidate

Merck and Daiichi Sankyo begin dosing in the phase III HERTHENA-Breast04 study on patritumab deruxtecan in certain breast cancer patients.

AZNPositive Net Change PFEPositive Net Change MRKPositive Net Change

Ahan Chakraborty

Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?

ALNY's Amvuttra revenues surge with 89% sales growth in H1 and a key label expansion, but faces tough competition in the ATTR-CM market.

ALNYPositive Net Change PFEPositive Net Change BBIONegative Net Change

Zacks Equity Research

INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug

Inovio stock surges 21% after the FDA gives green light to begin a rolling BLA for its RRP drug INO-3107, with plans to seek priority review.

INOPositive Net Change CRMDNegative Net Change KNSAPositive Net Change PGENPositive Net Change

Kinjel Shah

Can Pfizer's Cost Cuts and New Drugs Offset Upcoming Headwinds?

Pfizer braces for patent losses, IRA pressure and COVID uncertainty, but cost cuts and key drugs may still support profit growth.

JNJPositive Net Change PFEPositive Net Change MRKPositive Net Change LLYPositive Net Change

Kanishka Das

Will Weak Gardasil Sales Continue to Be a Drag on MRK's Top Line?

Merck halts Gardasil shipments in China after weak demand hurts sales, with declines also seen in Japan.

SNYNegative Net Change AZNPositive Net Change MRKPositive Net Change

Sundeep Ganoria

CRSP vs. BEAM: Which Gene Editing Stock Holds More Potential Right Now?

CRISPR Therapeutics gains momentum with Casgevy sales and a broader pipeline, while Beam Therapeutics advances base-editing therapies still in early stages.

VRTXPositive Net Change BEAMPositive Net Change CRSPPositive Net Change